Menu


- Home
- Expertise
- What we do
- What we have
- Who we are
- Resource Library
NEW DATA available in the PHARMO Database Network – Ambulatory Consultations This new dataset comprises all ambulatory consultations (i.e. out-patient records). This is a great asset for PHARMO, as all specialist visits and out-patient procedure...
Onderzoekers van Amsterdam UMC hebben een algoritme ontwikkeld dat voor patiënten van elke huisartspraktijk het risico berekent om ernstig ziek te worden door het coronavirus. www.amc.nl/web/nieuws-en-verhalen/actueel/actueel/algoritme-berekent-k...
Calling academics and researchers to join the upcoming webinar “Real world research on medicines: contribution of the European Network of Centres in Pharmacoepidemiology and Pharmacovigilance (ENCePP)” on March 8th. Please register via the below ...
Annual Conference International Society for Pharmacoepidemiology ICPE All AccessVirtual Event ( September 16-17, 2020) We are pleased to announce that PHARMO will present their study ‘Infliximab Use in the Netherlands: Uptake And Characteristic...
Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je ervaring als onderzoeker en heb je affiniteit met het vertalen van de vragen en onderzoek behoeften van de klant naar een onderzoeksvoorstel/-project?Heb je internationale commerc...
As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.
Read more
PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.
Read moreImpact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands
Read moreNo Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
Read moreTrends in mortality, cardiovascular complications, and risk factors in type 2 diabetes
Read moreThe risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression
Read more